Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eclipse-RT and Tislelizumab in Bulky Tumors
NCT06349837Phase 1Recruiting
- Sponsor
- Sichuan University
- Start
- Apr 2024
- Primary completion
- Mar 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tislelizumab in solid tumor, sponsored by Sichuan University. Primary endpoint: Dose Limiting Toxicities at 24 months. Started Apr 2024; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06349837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06349837.